莫西沙星超短程治疗初治菌阳肺结核患者的疗效与安全性

发布时间：2018-01-10 16:43

本文关键词：莫西沙星超短程治疗初治菌阳肺结核患者的疗效与安全性　出处：《中国医药指南》2017年04期 　论文类型：期刊论文

【摘要】：目的分析探讨莫西沙星超短程治疗初治菌阳肺结核患者的疗效与安全性。方法选2012年4月至2015年7月来我院接受初治菌阳肺结核的120例患者,分为对照组和实验组两组,每组60例患者,实验组患者采用莫西沙星超短程治疗方案进行治疗,对照组患者采用常规治疗方案进行治疗,所有患者均获得随访。结果在治疗后7周,实验组患者中出现痰结核菌转阴的有56例,对照组患者中出现痰结核菌转阴的有42例,治疗10周后,实验组和对照组患者中出现痰结核菌转阴的患者分别为58、44例,两组之间比较,差异显著,具有统计学意义(P0.05)。结论莫西沙星超短程治疗初治菌阳肺结核患者的临床效果显著,能够有效的改善患者的临床症状,并且莫西沙星药物使用安全可靠,值得临床推广和使用。
[Abstract]:Objective to analyze the efficacy and safety of moxifloxacin in the treatment of primary bacterial positive pulmonary tuberculosis. Methods 120 cases of newly treated positive pulmonary tuberculosis from April 2012 to July 2015 in our hospital were selected. The patients in the experimental group were treated with moxifloxacin ultrashort therapy, and the patients in the control group were treated with routine therapy. Results at 7 weeks after treatment, 56 cases of sputum tuberculosis turned negative in the experimental group and 42 cases in the control group, 10 weeks after treatment. In the experimental group and the control group, the number of patients with sputum tuberculous bacilli turning negative was 58.44 cases, the difference between the two groups was significant. Conclusion moxifloxacin ultrashort treatment of patients with bacterial positive pulmonary tuberculosis has a significant clinical effect, can effectively improve the clinical symptoms of patients. The use of moxifloxacin is safe and reliable and worthy of clinical promotion and use.
【作者单位】：阜新市传染病医院;
【分类号】：R521
【正文快照】： 近年来,我国肺结核的发病率越来越高,而现在治疗肺结核的药物主要为喹诺酮类药物[1],该类药物具有较高的抗结核活性,并且在临床上得到广泛的应用。但是对于肺结核的治疗方案,临床上却没有更为明确的方案[2]。本次研究2012年4月至2015年7月来我院接受初治菌阳肺结核的120例患者

【参考文献】